Health-related quality of life in dogs treated with electrochemotherapy and/or interleukin-12 gene electrotransfer.
dogs
electrochemotherapy
gene electrotransfer
health-related quality of life
interleukin-12
Journal
Veterinary medicine and science
ISSN: 2053-1095
Titre abrégé: Vet Med Sci
Pays: England
ID NLM: 101678837
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
30
07
2019
revised:
28
10
2019
accepted:
08
12
2019
pubmed:
8
1
2020
medline:
16
3
2021
entrez:
8
1
2020
Statut:
ppublish
Résumé
The aim of this study was to evaluate the owners' perception of health-related quality of life (HRQoL) of dogs after treatment with electrochemotherapy (ECT) alone or combined with interleukin-12 gene electrotransfer (IL-12 GET) and/or surgery. The owners of 44 dogs with histologically different tumours were offered the »Cancer Treatment Form« at least one month after treatment. The owners assessed their dogs' quality of life (QoL) after treatment as good (mean 7.4) (from 1-very poor to 10-excellent) and the general health compared with the initial diagnosis of cancer as improving (mean 3.9) (from 1-worse to 5-better). The assessment of the current QoL was better within the group of dogs treated with non-invasive treatment (ECT and/or IL-12 GET only), compared with those that received invasive treatment, where, in addition to ECT and/or IL-12 GET, surgery was performed (p < .05). The owners of dogs that achieved an objective response (OR) to the treatment assessed the QoL as significantly better compared with those whose dogs did not respond to the treatment (p < .05). The majority of the owners (86.4%) would opt for the therapy again, regardless of the financial costs. In conclusion, the results of this study demonstrate that the majority of the owners of dogs assessed their dogs' QoL as good and felt that it improved after the treatment, especially in dogs, treated with non-invasive treatment and in those that responded to the treatment. This supports further use of ECT and IL-12 GET as suitable methods for the treatment of selected tumours in veterinary medicine.
Identifiants
pubmed: 31910331
doi: 10.1002/vms3.232
pmc: PMC7397887
doi:
Substances chimiques
Interleukin-12
187348-17-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-298Informations de copyright
© 2020 The Authors. Veterinary Medicine and Science Published by John Wiley & Sons Ltd.
Références
Vet Dermatol. 2011 Aug;22(4):335-43
pubmed: 21410569
J Am Vet Med Assoc. 2014 Sep 1;245(5):527-33
pubmed: 25148094
J Am Vet Med Assoc. 2013 Jun 15;242(12):1679-87
pubmed: 23725431
Radiol Oncol. 2017 Sep 14;51(3):286-294
pubmed: 28959165
Res Vet Sci. 2019 Feb;122:40-49
pubmed: 30453179
J Am Vet Med Assoc. 2012 May 15;240(10):1188-93
pubmed: 22559108
Eur J Cancer. 2005 Aug;41(12):1697-709
pubmed: 16043345
Vet Med Sci. 2020 Aug;6(3):290-298
pubmed: 31910331
Vet Comp Oncol. 2015 Sep;13(3):176-83
pubmed: 23534501
In Vivo. 2009 Jan-Feb;23(1):55-62
pubmed: 19368125
Vet Comp Oncol. 2017 Sep;15(3):684-691
pubmed: 27140826
Vet Comp Oncol. 2017 Sep;15(3):775-784
pubmed: 27001443
J Feline Med Surg. 2014 Apr;16(4):291-9
pubmed: 24127456
Can Vet J. 2017 Sep;58(9):941-951
pubmed: 28878418
J Feline Med Surg. 2018 Apr;20(4):356-361
pubmed: 28569081
Tierarztl Prax Ausg K Kleintiere Heimtiere. 2014;42(3):157-65
pubmed: 24920142
Vet J. 2016 Nov;217:18-25
pubmed: 27810205
Vet Dermatol. 2011 Aug;22(4):344-51
pubmed: 21435044
Cancer Gene Ther. 2010 Aug;17(8):571-8
pubmed: 20414325
Prev Vet Med. 2016 May 1;127:64-9
pubmed: 27094142
Acta Vet Hung. 2015 Dec;63(4):451-7
pubmed: 26599092
Clin Cancer Res. 2009 Jun 1;15(11):3856-65
pubmed: 19470739
Vet J. 2018 Sep;239:59-64
pubmed: 30197111
Eur J Surg Oncol. 2016 Dec;42(12):1914-1923
pubmed: 27424789
J Vet Intern Med. 2016 Jan-Feb;30(1):183-91
pubmed: 26567089
J Cell Mol Med. 2015 Mar;19(3):664-75
pubmed: 25628149
J Vet Intern Med. 2010 Nov-Dec;24(6):1421-6
pubmed: 20738770
J Feline Med Surg. 2008 Feb;10(1):73-81
pubmed: 17827048
JPEN J Parenter Enteral Nutr. 1992 Nov-Dec;16(6 Suppl):106S-111S
pubmed: 1287221
Anticancer Res. 2005 Mar-Apr;25(2A):839-45
pubmed: 15868917
Vet Comp Oncol. 2017 Jun;15(2):641-654
pubmed: 26840222
J Small Anim Pract. 2003 Mar;44(3):100-3
pubmed: 12653322
Vet Dermatol. 2016 Aug;27(4):247-e58
pubmed: 27292136
J Am Vet Med Assoc. 2005 Jun 1;226(11):1864-8
pubmed: 15934254
Can Vet J. 2013 Jun;54(6):606-9
pubmed: 24155455
J Am Vet Med Assoc. 2008 Jul 1;233(1):104-8
pubmed: 18593317
Vet Rec. 2016 Sep 3;179(9):229
pubmed: 27329504
Vet Rec. 2015 Sep 26;177(12):306-15
pubmed: 26405128
J Am Vet Med Assoc. 2008 Sep 15;233(6):925-30
pubmed: 18795853
J Vis Exp. 2016 Oct 24;(116):
pubmed: 27805594
J Vet Intern Med. 2012 Jul-Aug;26(4):953-61
pubmed: 22646241
Diagn Interv Radiol. 2018 Sep;24(5):268-275
pubmed: 30211680
Curr Gene Ther. 2010 Aug;10(4):300-11
pubmed: 20560875
Vet Comp Oncol. 2011 Sep;9(3):172-82
pubmed: 21848620